WHO ICTRP trial
Effect of SGLT2 inhibitor on energy metabolism in patients with type 2 diabetes
JPRN-UMIN000024822 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000024822 |
|---|---|
| Public title | Effect of SGLT2 inhibitor on energy metabolism in patients with type 2 diabetes |
| Scientific title | Effect of SGLT2 inhibitor on energy metabolism in patients with type 2 diabetes - Effect of SGLT2 inhibitor on energy metabolism in patients with type 2 diabetes |
| Primary sponsor | Kyoto University Graduate School of Medicine |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Not selected |
| Countries | Japan |
| Conditions | Type 2 diabetes |
| Interventions | SGLT2 innhibitor: once-daily SGLT2 inhibitor (dapagliflozin 5mg) as add-on to the conventional treatment for 1 week. Low-carbo diet: low-carbo (40-45%) diet as add-on to the conventional treatment for 1 week. Control: conventional (55-60%… |
| Registration date | Jan 1, 2017 |
| Target size | 100 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: